EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Checkpoint blockade and the stem‐like T cell trade‐off

Julie M Mazet, Johanna A Joyce iD

Molecular Oncology · 2026-05 · 20 (5) · 1093-1097

DOI: 10.1002/1878-0261.70257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 20.04.2026. Verfasst von Julie M Mazet und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Fundamental Oncology, University of Lausanne, Switzerland. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplastic Stem Cells, T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stem‐like T cells are central to the efficacy of programmed cell death protein 1 (PD1) blockade, sustaining long‐term immune responses by serving as a renewable reservoir for anti‐tumor effector CD8+ T cells. However, the mechanisms governing their maintenance and regulation in cancer remain incompletely understood. Addressing this gap, Hor et al . combined high‐dimensional 3D‐imaging with immunological profiling to define the niche of stem‐like T cells within tumor‐draining lymph nodes in murine cancer models. Their study identifies a critical role for conventional type 1 dendritic cells (cDC1s) and the PD1 pathway in preserving high‐affinity tumor‐specific stem‐like T cells. cDC1s deliver sustained T‐cell receptor (TCR) stimulation together with PD‐L1/2 co‐inhibitory signals that support stemness, proliferation, and survival. Strikingly, disruption of PD1 signaling transiently enhances effector T cell expansion but promotes differentiation and apoptosis of stem‐like T cells, ultimately depleting this essential pool. These findings reveal a potential long‐term vulnerability of immune checkpoint blockade, particularly when tumors are not eradicated during the initial treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplastic Stem CellsT-LymphocytesAnimalsHumansProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Stem‐like T cellscancer immunityimmune checkpoint blockade

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Fundamental Oncology, University of Lausanne, Switzerland.
  • Ludwig Institute for Cancer Research, University of Lausanne, Switzerland.
  • Agora Cancer Research Centre, Lausanne, Switzerland.

ORCID-Profile: Johanna A Joyce

Zitieren

APA

Mazet, J. M., & Joyce, J. A. (2026). Checkpoint blockade and the stem‐like T cell trade‐off. Molecular Oncology, 20(5), 1093-1097. https://doi.org/10.1002/1878-0261.70257

Vancouver

Mazet JM, Joyce JA. Checkpoint blockade and the stem‐like T cell trade‐off. Molecular Oncology. 2026;20(5):1093-1097. doi:10.1002/1878-0261.70257

BibTeX
@article{Mazet2026,
  author = {Mazet, Julie M and Joyce, Johanna A},
  title = {Checkpoint blockade and the stem‐like T cell trade‐off},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {5},
  pages = {1093--1097},
  doi = {10.1002/1878-0261.70257}
}
Kostenlos starten →